Group A streptococcal vaccines.

Abstract

The pathogenesis of group A streptococcal infections, and antigens that contribute to protective immune responses are reviewed. Several approaches to vaccine development are discussed. Data are provided from preclinical studies of multivalent M protein-based vaccines that evoke protective antibodies in laboratory animals. Also discussed are future strategies for the development of broadly protective vaccines, and their potential impact on the incidence of streptococcal infections, and acute rheumatic fever.

• Authors: J B Dale
• Journal: Infectious disease clinics of North America (Infect Dis Clin North Am) Vol. 13 Issue 1 Pg. 227-43, viii (Mar 1999) ISSN: 0891-5520 [Print] United States
• PMID: 10198801 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Antigens, Bacterial
• Bacterial Vaccines
• Vaccines, Synthetic

Topics

• Animals
• Antigens, Bacterial (immunology)
• Bacterial Vaccines (immunology)
• Humans
• Mice
• Rabbits
• Streptococcal Infections (prevention & control)
• Streptococcus pyogenes (immunology)
• Vaccines, Synthetic (immunology)